Biogen (BIIB) Other Non-Current Liabilities (2009 - 2026)

Biogen's Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $787.1 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 4.71% year-over-year to $787.1 million; the TTM figure through Mar 2026 stood at $787.1 million (up 4.71% YoY), while the FY2025 annual figure was $748.5 million, up 2.21% from the prior year.
• Other Non-Current Liabilities was $787.1 million for Q1 2026 at Biogen, up from $748.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $1.3 billion in Q1 2022 to a low of $556.7 million in Q2 2024.
• Historically, Other Non-Current Liabilities has averaged $852.8 million across 5 years, with a median of $777.1 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities plunged 37.58% in 2023, then soared 43.63% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $944.2 million in 2022, then fell by 17.27% to $781.1 million in 2023, then decreased by 6.25% to $732.3 million in 2024, then gained by 2.21% to $748.5 million in 2025, then gained by 5.16% to $787.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $787.1 million (Q1 2026), $748.5 million (Q4 2025), and $761.8 million (Q3 2025), per Business Quant data.